Development of Middle East Respiratory Syndrome Coronavirus vaccines–advances and challenges

Human Vaccines and Immunotherapeutics

Volumn 14, Issue 2, 2018, Pages 304-313

  Cho, Heeyoun ^a   Excler, Jean Louis ^a   Kim, Jerome H ^a   Yoon, In Kyu ^a  

^a International Vaccine Institute   (South Korea)

Author keywords

MERS coronavirus; Middle East Respiratory Syndrome; receptor binding domain; spike protein; vaccine

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; LIVE VACCINE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; PHOSPHOLIPID ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; HUMAN; IMMUNE RESPONSE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; REVIEW; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS VIRULENCE; CORONAVIRUS INFECTION; IMMUNOLOGY;

CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VACCINES, DNA; VIRAL VACCINES;

EID: 85041500705     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1389362     Document Type: Review

References (101)

1. World Health Organization. Revised case definition for reporting to WHO Middle East respiratory syndrome coronavirus 2014. www.who.int/csr/disease/coronavirus_infections/case_definition_jul2014/en.
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–20. doi:10.1056/NEJMoa1211721. PMID:23075143.
3. Chan RW, Hemida MG, Kayali G, Chu DK, Poon LL, Alnaeem A, Ali MA, Tao KP, Ng HY, et al. Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study. Lancet Respir Med. 2014;2:813–22. doi:10.1016/S2213-2600(14)70158-4. PMID:25174549.
4. Raj VS, Farag EA, Reusken CB, Lamers MM, Pas SD, Voermans J, Smits SL, Osterhaus AD, Al-Mawlawi N, Al-Romaihi HE, et al. Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. Emerg Infect Dis. 2014;20:1339–42. doi:10.3201/eid2008.140663. PMID:25075761.
5. Chowell G, Blumberg S, Simonsen L, Miller MA, Viboud C. Synthesizing data and models for the spread of MERS-CoV, 2013: key role of index cases and hospital transmission. Epidemics. 2014;9:40–51. doi:10.1016/j.epidem.2014.09.011. PMID:25480133.
6. Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus: transmission and phylogenetic evolution. Trends Microbiol. 2014;22:573–9. doi:10.1016/j.tim.2014.08.001. PMID:25178651.
7. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369:407–16. doi:10.1056/NEJMoa1306742. PMID:23782161.
8. World Health Organization. Middle East Respiratory Syndrome coronavirus (MERS-CoV). 2017. http://www.who.int/emergencies/mers-cov/en/.
9. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) maps and epicurves 2017. http://www.who.int/csr/disease/coronavirus_infections/maps-epicurves/en/.
10. Chen X, Chughtai AA, Dyda A, MacIntyre CR. Comparative epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia and South Korea. Emerg Microbes Infect. 2017;6:e51. doi:10.1038/emi.2017.40. PMID:28588290.
11. Chowell G, Abdirizak F, Lee S, Lee J, Jung E, Nishiura H, Vibound C. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med. 2015;13:210 doi:10.1186/s12916-015-0450-0. PMID:26336062.
12. Guery B, Poissy J, el Mansouf L, Sejourne C, Ettahar N, Lemaire X, Vuotto F, Goffard A, Behillil S, Enouf V, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet. 2013;381(9885):2265–72. doi:10.1016/S0140-6736(13)60982-4. PMID:23727167.
13. Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V, Campese C, Guery B, Prouvost H, Lemaire X, et al. First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill. 2013;18(24). PMID:23787161.
14. World Health Organization. Laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV). June 2015. www.who.int/csr/disease/coronavirus_infections/mers-laboratory-testing/en/.
15. Al Johani S, Hajeer AH. MERS-CoV diagnosis: An update. J Infect Public Health. 2016;9(3):216–9. doi:10.1016/j.jiph.2016.04.005. PMID:27106390.
16. Chan JF, Choi GK, Tsang AK, Tee KM, Lam HY, Yip CC, To KK, Cheng VC, Yeung ML, Lau SK, et al. Development and Evaluation of Novel Real-Time Reverse Transcription-PCR Assays with Locked Nucleic Acid Probes Targeting Leader Sequences of Human-Pathogenic Coronaviruses. J Clin Microbiol. 2015;53:2722–6. doi:10.1128/JCM.01224-15. PMID:26019210.
17. Prevention CfDCa. Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 2015. Available from: http://www.cdc.gov/coronavirus/mers/downloads/guidelines-clinical-specimens.pdf.
18. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015;12:222. doi:10.1186/s12985-015-0439-5. PMID:26695637.
19. Park WB, Perera RA, Choe PG, Lau EH, Choi SJ, Chun JY, Oh HS, Song KH, Bang JH, Kim ES, et al. Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea. Emerg Infect Dis. 2015;21:2186–9. doi:10.3201/eid2112.151421. PMID:26583829.
20. Chen Y, Chan KH, Kang Y, Chen H, Luk H, Poon RW, Chan JF, Yuen KY, Xia N, Lau SK, et al. A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus. Emerg Microbes Infect. 2015;4(4):e26. doi:10.1038/emi.2015.26.
21. Song D, Ha G, Serhan W, Eltahir Y, Yusof M, Hashem F, Elsayed E, Marzoug B, Abdelazim A, Al Muhairi S. Development and validation of a rapid immunochromatographic assay for detection of Middle East respiratory syndrome coronavirus antigen in dromedary camels. J Clin Microbiol. 2015;53(4):1178–82. doi:10.1128/JCM.03096-14. PMID:25631809.
22. Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23:468–78. doi:10.1016/j.tim.2015.06.003. PMID:26206723.
23. Qian Z, Dominguez SR, Holmes KV. Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS One. 2013;8:e76469. doi:10.1371/journal.pone.0076469. PMID:24098509.
24. Kim Y, Cheon S, Min CK, Sohn KM, Kang YJ, Cha YJ, Kang JI, Han SK, Ha NY, Kim G, et al. Spread of Mutant Middle East Respiratory Syndrome Coronavirus with Reduced Affinity to Human CD26 during the South Korean Outbreak. MBio. 2016;7:e00019–16. doi:10.1128/mBio.00019-16. PMID:26933050.
25. Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y, Tallarico AS, Sheehan J, Zhu Q, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A. 2014;111:E2018–26. doi:10.1073/pnas.1402074111. PMID:24778221.
26. Tang F, Quan Y, Xin ZT, Wrammert J, Ma MJ, Lv H, Wang TB, Yang H, Richardus JH, Liu W, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186:7264–8. doi:10.4049/jimmunol.0903490. PMID:21576510.
27. Sui J, Deming M, Rockx B, Liddington RC, Zhu QK, Baric RS, Marasco WA. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol. 2014;88:13769–80. doi:10.1128/JVI.02232-14. PMID:25231316.
28. Faure E, Poissy J, Goffard A, Fournier C, Kipnis E, Titecat M, Bortolotti P, Martinez L, dubucquoi S, Dessein R, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One. 2014;9:e88716. doi:10.1371/journal.pone.0088716. PMID:24551142.
29. Corman VM, Albarrak AM, Omrani AS, Albarrak MM, Farah ME, Almasri M, Muth D, Sieberg A, Meyer B, Assiri AM, et al. Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection. Clin Infect Dis. 2016;62(4):477–83. PMID:26565003.
30. Min CK, Cheon S, Ha NY, Sohn KM, Kim Y, Aigerim A, Shin HM, Choi JY, Inn KS, Kim JH, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6:25359. doi:10.1038/srep25359. PMID:27146253.
31. Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY, Na SH, Kim M, Song KH, Bang JH, et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. J Korean Med Sci. 2016;31:1717–25. doi:10.3346/jkms.2016.31.11.1717. PMID:27709848.
32. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, Gale MJ, Baric RS, Enjuanes L, Gallagher T, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111:4970–5. doi:10.1073/pnas.1323279111. PMID:24599590.
33. Modjarrad K, Moorthy VS, Ben Embarek P, Van Kerkhove M, Kim J, Kieny MP. A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. Nat Med. 2016;22:701–5. doi:10.1038/nm.4131. PMID:27387881.
34. Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang Y, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014;88:7796–805. doi:10.1128/JVI.00912-14. PMID:24789777.
35. Agrawal AS, Ying T, Tao X, Garron T, Algaissi A, Wang Y, Wang L, Peng BH, Jiang S, Dimitrov DS, et al. Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Sci Rep. 2016;6:31629. doi:10.1038/srep31629. PMID:28442756.
36. Rabaan AA, Bazzi AM, Al-Ahmed SH, Al-Tawfiq JA. Molecular aspects of MERS-CoV. Front Med. 2017;11(3):365–77. doi:10.1007/s11684-017-0521-z.
37. Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, Matsushita H, Liu Y, Postnikova EN, Ork BL, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016;8:326ra21. doi:10.1126/scitranslmed.aaf1061. PMID:26888429.
38. Chen Y, Lu S, Jia H, Deng Y, Zhou J, Huang B, Yu Y, Lan J, Wang W, Lou Y, et al. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg Microbes Infect. 2017;6:e37. doi:10.1038/emi.2017.18. PMID:28536429.
39. Coleman CM, Matthews KL, Goicochea L, Frieman MB. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol. 2014;95(Pt 2):408–12. doi:10.1099/vir.0.060640-0. PMID:24197535.
40. de Wit E, Prescott J, Baseler L, Bushmaker T, Thomas T, Lackemeyer MG, Martellaro C, Milne-Price S, Haddock E, Haagmans B, et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One. 2013;8:e69127. doi:10.1371/journal.pone.0069127. PMID:23844250.
41. Yu P, Xu Y, Deng W, Bao L, Huang L, Xu Y, Yao Y, Qin, C. Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus. PLoS One. 2017;12:e0172093. doi:10.1371/journal.pone.0172093. PMID:28234937.
42. de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL, Fischer ER, Martellaro C, Okumura A, Chang J, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A. 2013;110:16598–603. doi:10.1073/pnas.1310744110. PMID:24062443.
43. Yao Y, Bao L, Deng W, Xu L, Li F, Lv Q, Yu P, Chen T, Xu Y, Zhu H, et al. An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J Infect Dis. 2014;209:236–42. doi:10.1093/infdis/jit590. PMID:24218506.
44. Falzarano D, de Wit E, Feldmann F, Rasmussen AL, Okumura A, Peng X, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS pathogens. 2014;10(8):e1004250. doi:10.1371/journal.ppat.1004250. PMID:25144235.
45. Adney DR, van Doremalen N, Brown VR, Bushmaker T, Scott D, de Wit E, Bowen RA, Munster VJ. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis. 2014;20:1999–2005. doi:10.3201/eid2012.141280. PMID:25418529.
46. Adney DR, Bielefeldt-Ohmann H, Hartwig AE, Bowen RA. Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas. Emerg Infect Dis. 2016;22(6):1031–7. doi:10.3201/eid2206.160192. PMID:27070385.
47. Agrawal AS, Garron T, Tao X, Peng BH, Wakamiya M, Chan TS, Couch RB, Tseng CT. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol. 2015;89:3659–70. doi:10.1128/JVI.03427-14. PMID:25589660.
48. Baseler L, de Wit E, Feldmann H. A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection. Vet Pathol. 2016;53:521–31. doi:10.1177/0300985815620845. PMID:26869154.
49. Goncalves GA, Prather KL, Monteiro GA, Carnes AE, Prazeres DM. Plasmid DNA production with Escherichia coli GALG20, a pgi-gene knockout strain: fermentation strategies and impact on downstream processing. Journal of biotechnology. 2014;186:119–27. doi:10.1016/j.jbiotec.2014.06.008. PMID:24995846.
50. Roberts A, Lamirande EW, Vogel L, Jackson JP, Paddock CD, Guarner J, Zaki SR, Sheahan T, Baric R, Subbarao K. Animal models and vaccines for SARS-CoV infection. Virus research. 2008;133(1):20–32. doi:10.1016/j.virusres.2007.03.025. PMID:17499378.
51. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clinical and Vaccine Immunology: CVI. 2006;13(11):1267–77. doi:10.1128/CVI.00162-06. PMID:16988008.
52. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26:6338–43. doi:10.1016/j.vaccine.2008.09.026. PMID:18824060.
53. Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7:301ra132. doi:10.1126/scitranslmed.aac7462. PMID:26290414.
54. ClinicalTrials.gov. Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers 2017. https://clinicaltrials.gov/ct2/show/NCT02670187?term=GLS-5300&rank=1.
55. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees, CR, Zhou T, Yassine HM, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712. doi:10.1038/ncomms8712. PMID:26218507.
56. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PloS one. 2013;8(12):e81587. doi:10.1371/journal.pone.0081587. PMID:24324708.
57. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 2013;87(17):9939–42. doi:10.1128/JVI.01048-13. PMID:23824801.
58. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014;13(6):761–74. doi:10.1586/14760584.2014.912134. PMID:24766432.
59. Lan J, Deng Y, Chen H, Lu G, Wang W, Guo X, Lu Z, Gao GF, Tan W. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One. 2014;9:e112602. doi:10.1371/journal.pone.0112602. PMID:25405618.
60. Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, Tao X, Tasneem S, Lu L, Tseng CT, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016;13:180–90. doi:10.1038/cmi.2015.03. PMID:25640653.
61. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82–92. doi:10.1016/j.antiviral.2016.11.006. PMID:27840203.
62. McPherson C, Chubet R, Holtz K, Honda-Okubo Y, Barnard D, Cox M, Petrovsky N. Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant. Methods Mol Biol. 2016;1403:269–84. doi:10.1007/978-1-4939-3387-7_14. PMID:27076136.
63. Chen WH, Chag SM, Poongavanam MV, Biter AB, Ewere EA, Rezende W, Seid CA, Hudspeth EM, Pollet J, McAtee CP, et al. Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate. J Pharm Sci. 2017;106(8):1961–70. doi:10.1016/j.xphs.2017.04.037.
64. Yuan Y, Cao D, Zhang Y, Ma J, Qi J, Wang Q, Lu G, Wu Y, Yan J, Shi Y, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun. 2017;8:15092. doi:10.1038/ncomms15092. PMID:28393837.
65. Excler JL, Delvecchio CJ, Wiley RE, Williams M, Yoon IK, Modjarrad K, Bourjelal M, Moorthy VS, Hersi AS, Kim JH. Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015. Emerg Infect Dis. 2016;22(8). doi:10.3201/eid2208.160229. PMID:27439020.
66. Lan J, Yao Y, Deng Y, Chen H, Lu G, Wang W, Bao L, Deng W, Wei Q, Gao GF, et al. Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge. EBioMedicine. 2015;2:1438–46. doi:10.1016/j.ebiom.2015.08.031. PMID:26629538.
67. Wang C, Zheng X, Gai W, Zhao Y, Wang H, Wang H, Feng N, Chi H, Qiu B, Li N, et al. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget. 2017;8:12686–94. PMID:27050368.
68. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CT, Li F, Zhou Y, Jiang S, Du L. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments–the importance of immunofocusing in subunit vaccine design. Vaccine. 2014;32:6170–6. doi:10.1016/j.vaccine.2014.08.086. PMID:25240756.
69. Tao X, Garron T, Agrawal AS, Algaissi A, Peng BH, Wakamiya M, Chan TS, Lu L, Du L, Jiang S, et al. Characterization and Demonstration of value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol. 2015;90:57–67. doi:10.1128/JVI.02009-15. PMID:26446606.
70. Jiaming L, Yanfeng Y, Yao D, Yawei H, Linlin B, Baoying H, Jinghua Y, Gao GF, CHuan Q, Wenjie T. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35:10–8. doi:10.1016/j.vaccine.2016.11.064. PMID:27899228.
71. Tang J, Zhang N, Tao X, Zhao G, Guo Y, Tseng CT, Jiang S, Du L, Zhou Y. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 2015;11:1244–50. doi:10.1080/21645515.2015.1021527. PMID:25874632.
72. Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, Jiang S, Zhou Y, Du L. Recombinant receptor-binding domains of multiple MERS-coronaviruses induce cross-neutralizing antibodies against divergent human and camel MERS-coronaviruses and antibody-escape mutants. J Virol. 2016;91:01651–16.
73. Tai W, Zhao G, Sun S, Guo Y, Wang Y, Tao X, Tseng CK, Li F, Jiang S, Du L, et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016;499:375–82. doi:10.1016/j.virol.2016.10.005. PMID:27750111.
74. Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Glenn GM, Smith GE, Frieman MB. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32:3169–74. doi:10.1016/j.vaccine.2014.04.016. PMID:24736006.
75. Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC, Frieman MB. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 2017;35:1586–9. doi:10.1016/j.vaccine.2017.02.012. PMID:28237499.
76. Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu L, Kwilas SA, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine. 2016;34:1927–35. doi:10.1016/j.vaccine.2016.02.033. PMID:26921779.
77. Liu YV, Massare MJ, Pearce MB, Sun X, Belser JA, Maines TR, Creager HM, Glenn, GM, Pushko P, SMith GE, et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. Vaccine. 2015;33:2152–8. doi:10.1016/j.vaccine.2015.03.009. PMID:25772674.
78. Malczyk AH, Kupke A, Prufer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, et al. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. J Virol. 2015;89:11654–67. doi:10.1128/JVI.01815-15. PMID:26355094.
79. Guo X, Deng Y, Chen H, Lan J, Wang W, Zou X, Hung T, Lu Z, Tan W. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology. 2015;145:476–84. PMID:25762305.
80. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, et al. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. J Virol. 2015;89:8651–6. PMID:26018172.
81. Pichla-Gollon SL, Lin SW, Hensley SE, Lasaro MO, Herkenhoff-Haut L, Drinker M, Tatsis N, Gao GP, Wilson JM, Ertl HC, et al. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol. 2009;83(11):5567–73. PMID:19279092.
82. Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–6. PMID:15507655.
83. Haagmans BL, van den Brand JM, Raj VS, Volz A, Wohlsein P, Smits SL, Schipper D, Bestebroer TM, Okba N, Fux R, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351:77–81. PMID:26678878.
84. Warimwe GM, Gesharisha J, Carr BV, Otieno S, Otingah K, Wright D, Charleston B, Okoth E, Elena LG, Lorenzo G, et al. Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Sci Rep. 2016;6:20617. PMID:26847478.
85. Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines. 2013;12:379–93. PMID:23560919.
86. Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nebie I, Bliss C, Hodgson SH, Anagnostou NA, Snou GS, et al. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Mol Ther. 2016;24(8):1470–7. PMID:27109630.
87. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16(1):31–42. PMID:26546548.
88. Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, et al. Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med. 2017;376(10):928–38. doi:10.1056/NEJMoa1410863. PMID:25426834.
89. Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T, Warimwe G, et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35:3780–8. doi:10.1016/j.vaccine.2017.05.032. PMID:28579232.
90. Almazan F, DeDiego ML, Sola I, Zuniga S, Nieto-Torres JL, Marquez-Jurado S, Andres G, Enjuanes L. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio. 2013;4:e00650–13. doi:10.1128/mBio.00650-13. PMID:24023385.
91. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med. 2012;18(12):1820–6. Epub 2012/11/13. doi:10.1038/nm.2972. PMID:23142821.
92. Choi J, Kim MG, Oh YK, Kim YB. Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review. Expert Opin Ther Pat. 2017;27:721–31. doi:10.1080/13543776.2017.1281248. PMID:28121202.
93. Ulmer JB, Geall AJ. Recent innovations in mRNA vaccines. Curr Opin Immunol. 2016;41:18–22. doi:10.1016/j.coi.2016.05.008. PMID:27240054.
94. Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell. 2017;169:176. doi:10.1016/j.cell.2017.03.016. PMID:28340344.
95. Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89:2995–3007. doi:10.1128/JVI.02980-14. PMID:25520500.
96. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32:2100–8. doi:10.1016/j.vaccine.2014.02.004. PMID:24560617.
97. Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. 2014;88:8597–614. doi:10.1128/JVI.00983-14. PMID:24850731.
98. World Health Organization. WHO Target Product Profiles for MERS-CoV Vaccines. 2017. http://www.who.int/blueprint/what/research-development/MERS_CoV_TPP_15052017.pdf?ua=1.
99. Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2014;22:668–74. doi:10.1038/mt.2013.284. PMID:24374965.
100. Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB, Schnell MJ. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. García-Sastre A, ed. J Virol. 2017;91(2):e02040–16. doi:10.1128/JVI.02040-16. PMID:27807241.
101. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014;32:5975–82. doi:10.1016/j.vaccine.2014.08.058. PMID:25192975.